Intended for US audiences only
OPTUNE LUA STUDY RESULTS
In a clinical trial, Optune Lua was studied in 291 people with metastatic NSCLC.
Half used Optune Lua together with a class of immunotherapy known as PD-1/PD-L1 inhibitors or a type of chemotherapy called docetaxel, while the other half did not use Optune Lua.
The results:
People lived longer
People using Optune Lua with cancer drugs* lived for over 13 months, compared to nearly 10 months for people using cancer drugs* alone.
*Cancer drugs=PD-1/PD-L1 inhibitors or docetaxel.
About half of people using Optune Lua with cancer drugs* were still living at 1 year compared to 42% of people using cancer drugs* alone.
In a clinical study, using Optune Lua with specific cancer drugs* helped people live longer
Using Optune Lua with PD-1/PD-L1 inhibitors helped people live about 8 months longer than those who used PD-1/PD-L1 inhibitors alone.
61% of people using Optune Lua with PD-1/PD-L1 inhibitors were still living at 1 year compared with 46% of people using PD-1/PD-L1 inhibitors alone. This difference was statistically significant.
Using Optune Lua with docetaxel helped people live about 2 months longer than those using doxetacel alone.
46% of people using Optune Lua with docetaxel were still living at 1 year compared to 39% of people using docetaxel alone. The difference was not statistically significant.
People maintained their quality of life, including mental, emotional, and physical health, over 12 months while using Optune Lua with cancer drugs* or cancer drugs* alone.†
*Cancer drugs=PD-1/PD-L1 inhibitors or docetaxel.
†Based on the European Organisation for Research and Treatment of Cancer core quality of life questionnaire. Data was collected for 54 weeks.